IBDEI2TZ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47513,2)
 ;;=^5001660
 ;;^UTILITY(U,$J,358.3,47514,0)
 ;;=C84.70^^209^2346^37
 ;;^UTILITY(U,$J,358.3,47514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47514,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Unspec Site
 ;;^UTILITY(U,$J,358.3,47514,1,4,0)
 ;;=4^C84.70
 ;;^UTILITY(U,$J,358.3,47514,2)
 ;;=^5001661
 ;;^UTILITY(U,$J,358.3,47515,0)
 ;;=C84.71^^209^2346^38
 ;;^UTILITY(U,$J,358.3,47515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47515,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Head/Face/Neck Nodes
 ;;^UTILITY(U,$J,358.3,47515,1,4,0)
 ;;=4^C84.71
 ;;^UTILITY(U,$J,358.3,47515,2)
 ;;=^5001662
 ;;^UTILITY(U,$J,358.3,47516,0)
 ;;=C84.72^^209^2346^39
 ;;^UTILITY(U,$J,358.3,47516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47516,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Intrathoracic Nodes
 ;;^UTILITY(U,$J,358.3,47516,1,4,0)
 ;;=4^C84.72
 ;;^UTILITY(U,$J,358.3,47516,2)
 ;;=^5001663
 ;;^UTILITY(U,$J,358.3,47517,0)
 ;;=C84.73^^209^2346^40
 ;;^UTILITY(U,$J,358.3,47517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47517,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Intra-Abdominal Nodes
 ;;^UTILITY(U,$J,358.3,47517,1,4,0)
 ;;=4^C84.73
 ;;^UTILITY(U,$J,358.3,47517,2)
 ;;=^5001664
 ;;^UTILITY(U,$J,358.3,47518,0)
 ;;=C84.74^^209^2346^41
 ;;^UTILITY(U,$J,358.3,47518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47518,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Axilla/Upper Limb Nodes
 ;;^UTILITY(U,$J,358.3,47518,1,4,0)
 ;;=4^C84.74
 ;;^UTILITY(U,$J,358.3,47518,2)
 ;;=^5001665
 ;;^UTILITY(U,$J,358.3,47519,0)
 ;;=C84.75^^209^2346^42
 ;;^UTILITY(U,$J,358.3,47519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47519,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Ing Region/Lower Limb Nodes
 ;;^UTILITY(U,$J,358.3,47519,1,4,0)
 ;;=4^C84.75
 ;;^UTILITY(U,$J,358.3,47519,2)
 ;;=^5001666
 ;;^UTILITY(U,$J,358.3,47520,0)
 ;;=C84.76^^209^2346^43
 ;;^UTILITY(U,$J,358.3,47520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47520,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Intrapelvic Nodes
 ;;^UTILITY(U,$J,358.3,47520,1,4,0)
 ;;=4^C84.76
 ;;^UTILITY(U,$J,358.3,47520,2)
 ;;=^5001667
 ;;^UTILITY(U,$J,358.3,47521,0)
 ;;=C84.77^^209^2346^44
 ;;^UTILITY(U,$J,358.3,47521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47521,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Spleen
 ;;^UTILITY(U,$J,358.3,47521,1,4,0)
 ;;=4^C84.77
 ;;^UTILITY(U,$J,358.3,47521,2)
 ;;=^5001668
 ;;^UTILITY(U,$J,358.3,47522,0)
 ;;=C84.78^^209^2346^45
 ;;^UTILITY(U,$J,358.3,47522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47522,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,47522,1,4,0)
 ;;=4^C84.78
 ;;^UTILITY(U,$J,358.3,47522,2)
 ;;=^5001669
 ;;^UTILITY(U,$J,358.3,47523,0)
 ;;=C84.79^^209^2346^46
 ;;^UTILITY(U,$J,358.3,47523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47523,1,3,0)
 ;;=3^Anaplastic Large Cell Lymphoma,ALK-Negative,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,47523,1,4,0)
 ;;=4^C84.79
 ;;^UTILITY(U,$J,358.3,47523,2)
 ;;=^5001670
 ;;^UTILITY(U,$J,358.3,47524,0)
 ;;=C84.A0^^209^2346^113
 ;;^UTILITY(U,$J,358.3,47524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47524,1,3,0)
 ;;=3^Cutaneous T-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,47524,1,4,0)
 ;;=4^C84.A0
 ;;^UTILITY(U,$J,358.3,47524,2)
 ;;=^5001681
 ;;^UTILITY(U,$J,358.3,47525,0)
 ;;=C84.A1^^209^2346^106
 ;;^UTILITY(U,$J,358.3,47525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47525,1,3,0)
 ;;=3^Cutaneous T-Cell Lymphoma,Head/Face/Neck Nodes
